Document is current
Any future updates will be listed below
-
Authors
Belli, Stefania https://orcid.org/0000-0002-8348-3313
Pesapane, Ada
Servetto, Alberto
Esposito, Daniela
Napolitano, Fabiana https://orcid.org/0000-0002-2463-8952
Ascione, Claudia Maria https://orcid.org/0009-0000-9454-2828
Allotta, Alessandra https://orcid.org/0000-0002-7684-2031
Zambrano, Nicola
Marino, Federica Zito
Franco, Renato
Troiani, Teresa
Formisano, Luigi https://orcid.org/0000-0001-7205-5105
Bianco, Roberto https://orcid.org/0000-0003-3311-260X
-
Funding
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (AIRC IG 21339, MFAG 27826 - 2022, Fellowship for Italy 26795, MFAG 27826- 2022)
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 29 October 2022
Revised: 4 July 2023
Accepted: 31 July 2023
First Online: 11 August 2023
Competing interests
: AS reports honoraria from Eli Lilly, MSD, and Janssen and travel support from Bristol-Myers Squibb and AstraZeneca. LF declares the following competing interests: consultant and advisory board for Seagen, Amgen, BMS, MSD, Jansen and Pierre Fabre Pharma. RB declares the following competing interests: consultant and advisory board for BMS, MSD, Pfizer, AstraZeneca, Lilly and Novartis. The remaining authors declare no competing interests.
: CRC samples were retrospectively analysed at the Pathology Unit, University of Campania “L. Vanvitelli”. All patients agreed to participate in the study based on informed consent. Research Ethics Committee of the University of Campania “L. Vanvitelli” – AORN “Ospedale dei Colli” approved the study (reference n.0019530/2016). The study was performed in accordance with the Declaration of Helsinki.
